The company focuses on the development and commercialization of serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, for the treatment of pruritus associated with dermatologic conditions such as atopic dermatitis, psoriasis, and prurigo nodularis. They are also evaluating serlopitant for refractory chronic cough. VYNE Therapeutics plans to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the first half of 2018 and expects data from ongoing Phase 2 clinical trials in pruritus associated with atopic dermatitis, psoriasis, and refractory chronic cough in late 2018 or early 2019. In addition, the company is developing products containing BET inhibitor compounds and has two products, AMZEEQ and ZILXI, on the market for the treatment of acne.